Archive for the ‘Prostate prognosis’ Category

NEW PROSTATE CANCER INFOLINK: The idea that B2M expression or activity might have some significant impact on the androgen signaling axis in patients with prostate cancer is interesting, and has potential future implications for the prognosis and even the treatment of prostate cancer (assuming that these new findings can be confirmed by others). READ MORE> and HERE>

Read Full Post »

REUTERS: Even without treatment, only a small minority of men diagnosed with early-stage prostate cancer die from the disease, Swedish researchers report. READ MORE>

Read Full Post »

NEW PROSTATE CANCER INFOLINK: Research into a fused gene present in prostate cancer patients shows it is not a helpful marker in predicting the effectiveness of hormone therapy. READ MORE>

We will have to hope that presence of the TMPRSS2-ERG fusion gene can be used to predict something else about prostate cancer — otherwise what we will have is a very common “marker” that has no apparent clinical value.

Read Full Post »

URO TODAY: There is no evidence that tumour volume is an independent predictor of prostate cancer outcome and it should not be considered as a marker of tumour risk, behaviour or prognosis. READ MORE>

Read Full Post »

URO TODAY: Measuring DNA in prostate cancer tissue samples and samples from adjacent benign areas helps predict if treatment for low-grade disease will be needed. READ MORE>

Read Full Post »

URO TODAY: A new Japanese risk assessment system that ranks advanced prostate cancer patients out of 12 on Gleason score, PSA level, and clinical stage is the first for men undergoing primary androgen deprivation therapy. READ MORE>

Read Full Post »

JULY 31: URO TODAY: What’s the most accurate way your specialist can predict your fate when you first learn you have prostate cancer? Using something called a nomogram, according to latest analysis. READ MORE>

Researchers at the University of Montreal Health Center reviewed tools available to clinicians involved in treatment decisions in newly diagnosed prostate cancer and examined their accuracy to provide individual life expectancy.

“…nomograms provide the most accurate health-adjusted life expectancy prognostication,” they conclude.

What’s a nomogram?

It’s a calculation that gives an estimate – in this case, of life expectancy – after known information is fed into it.

The Memorial Sloan Kettering Cancer Center in the US has one for prostate cancer on its website. Anyone who knows the results of PSA, biopsy and Gleason grade can use it: CLICK HERE>

Here’s an example:


Read Full Post »

Older Posts »